Product Information
LINZESS 290 MCG CAPSULE is a brand product labeled by Allergan, Inc., priced at $9.0193 per EA under NDC 00456120230. Its NADAC has been published 657 times since Nov 28, 2013.
Strength
290 ug/1
Manufacturer
Allergan, Inc.NDC
00456120230
Classification
Brand
Dosage Form
CAPSULE, GELATIN COATED
Route
ORAL
Last Updated
6/17/2026
Active Ingredients
LINACLOTIDEApproval Type
New Drug (NDA)
FDA Application
NDA202811On Market Since
9/8/2012
Pharmacological Classes
Price Statistics
The NADAC for LINZESS 290 MCG CAPSULE has been published 657 times since Nov 28, 2013, and over the history we have for it it has risen 31.1%. The table below summarizes its recorded NADAC range and movement.
| Current price | $9.0193 per EA |
|---|---|
| All-time high | $18.1590 (May 14, 2025) |
| All-time low | $6.8815 (Nov 28, 2013) |
| 52-week high | $18.1469 |
| 52-week low | $9.0193 |
| Median price | $13.5666 |
| Average price | $13.2246 |
| Largest weekly change | -50.3% (Jan 14, 2026) |
| Weeks tracked | 657 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient, strength, and dosage form. Compare the broader picture on the linaclotide market page.
Lowest-Cost Alternatives
No alternatives available
Frequently asked questions
What is the NADAC price of LINZESS 290 MCG CAPSULE?
The current National Average Drug Acquisition Cost (NADAC) for LINZESS 290 MCG CAPSULE, manufactured by Allergan, Inc., is $9.0193 per EA (NDC 00456120230), effective Jun 24, 2026.
How has the price of LINZESS 290 MCG CAPSULE changed over time?
Over the history we have for it, the NADAC for LINZESS 290 MCG CAPSULE has risen 31.1%. It has been tracked across 657 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for LINZESS 290 MCG CAPSULE?
Since Nov 28, 2013, the NADAC for LINZESS 290 MCG CAPSULE has ranged from a low of $6.8815 (Nov 28, 2013) to a high of $18.1590 (May 14, 2025), with a median of $13.5666 per EA.
Are there cheaper alternatives to LINZESS 290 MCG CAPSULE?
No other NADAC-published product currently shares the active ingredient, strength, and dosage form of LINZESS 290 MCG CAPSULE, so no direct lower-cost alternative is listed.
Who manufactures LINZESS 290 MCG CAPSULE?
LINZESS 290 MCG CAPSULE (NDC 00456120230) is labeled by Allergan, Inc., and CMS classifies it as a brand product.
Related Drugs
Same classification